Focused On-demand Library for Zinc finger FYVE domain-containing protein 26

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q68DK2

UPID:

ZFY26_HUMAN

Alternative names:

FYVE domain-containing centrosomal protein; Spastizin

Alternative UPACC:

Q68DK2; B1B5Y3; B4E2U3; O15035; Q68DT9; Q6AW90; Q6ZR50; Q7Z3A4; Q7Z3I1; Q8N4W7; Q96H43

Background:

Zinc finger FYVE domain-containing protein 26, also known as Spastizin or FYVE domain-containing centrosomal protein, plays a crucial role in cytokinesis, specifically in the abcission step. It is recruited to the midbody during cytokinesis, acting as a regulator of abcission. Additionally, it is implicated in the efficient repair of DNA double-strand breaks through homologous recombination.

Therapeutic significance:

Spastizin is linked to Spastic paraplegia 15, a neurodegenerative disorder characterized by progressive weakness and spasticity of the lower limbs, among other neurological symptoms. Understanding the role of Spastizin could lead to novel therapeutic strategies for this condition, potentially addressing symptoms and progression.